The contents of Ingrezza (valbenazine) can be taken from their capsules and crushed before being sprinkled on soft foods…
Lindsey Shapiro, PhD
Lindsey earned her PhD in neuroscience from Emory University in Atlanta, where she studied novel therapeutic strategies for treatment-resistant forms of epilepsy. She was awarded a fellowship from the American Epilepsy Society in 2019 for this research. Lindsey also previously worked as a postdoctoral researcher, studying the role of inflammation in epilepsy and Alzheimer’s disease.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Lindsey Shapiro, PhD
Blocking immune system proteins that are part of the body’s complement cascade — which helps the immune system to fight…
A lab-made version of a plant enzyme prevented toxic huntingtin protein clumps — that drive Huntington’s disease from forming…
The benefits of Ingrezza (valbenazine) for people with Huntington’s disease — reductions in uncontrolled movements and gains in…
Caregivers of people with Huntington’s disease want support programs that will help them in balancing their own care needs…
With early data on AMT-130Â for Huntington’s disease reportedly looking promising, uniQure said it’s planning to meet early…
PTC Therapeutics’ Huntington’s disease treatment candidate PTC518 is well-tolerated and lowers blood levels of the huntingtin protein (HTT) in…
Note: This story was updated May 16, 2023, to correct the duration of ANX005 infusions. Only the first loading dose…
The last patient has completed the final visit in the Phase 3 PROOF-HD trial testing oral pridopidine for…
Enrollment is underway in a Phase 2 clinical trial testing Roche’s therapeutic candidate tominersen in people with…